Histone Deacetylase Inhibitor Therapy in Epithelial Ovarian Cancer

Since epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in ovarian cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In this review, we discuss the...

Descripción completa

Detalles Bibliográficos
Autores principales: Takai, Noriyuki, Narahara, Hisashi
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801002/
https://www.ncbi.nlm.nih.gov/pubmed/20052384
http://dx.doi.org/10.1155/2010/458431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801002/
https://www.ncbi.nlm.nih.gov/pubmed/20052384
http://dx.doi.org/10.1155/2010/458431

Ejemplares similares